人工重组促红细胞生成素的药物治疗及免疫耐药的研究进展  

Research progress of Drug therapy and Immune resistance of Artificial Recombinant Erythropoietin

作　　者：赵芪 刘艳姝[1] 刘红艳[1] Zhao Qi;Liu Yanshu;Liu Hongyan(The First Affiliated Hospital of Jiamusi University,Jiamusi 154000,China)

机构地区：[1]佳木斯大学附属第一医院,黑龙江佳木斯154000

出　　处：《广东化工》2021年第8期166-167,共2页Guangdong Chemical Industry

摘　　要：重组促红细胞生成素(erythropoietin,EPO)是一种含165个氨基酸的糖蛋白,作为一种细胞因子和生长因子,可以影响多个器官。除了促进红细胞生成外,对非红细胞也有细胞保护作用。自重组人促红细胞生成素(rhEPO)的开发以来,肾性贫血的治疗发生了革命性的变化,但是关于应用促红细胞生成素不良反应的报道日益增多。所以进一步研究促红细胞生成素的药物作用和免疫耐药及不良反应对肾性贫血的治疗有非常重要的意义。Erythropoietin(EPO) is a glycoprotein with 165 amino acids. As a cytokine and growth factor, it can affect many organs. In addition to promoting erythropoiesis, it also has cytoprotective effect on non erythrocytes. Since the development of recombinant human erythropoietin(rhEPO), revolutionary changes have taken place in the treatment of renal anemia, but, there are more and more reports about the adverse reactions of erythropoietin. Therefore, further study of erythropoietin drug effect and immune resistance and adverse reactions is of great significance for the treatment of renal anemia.

关 键 词：药物治疗 免疫耐药 造血作用 非造血作用 不良反应 

分 类 号：TQ[化学工程]